Lemborexant for insomnia in people with opioid use disorder taking buprenorphine
Tests lemborexant against placebo for sleep and mood in people with opioid use disorder.
Key facts
- Who runs it
- Virginia Commonwealth University
- Where
- Richmond, United StatesSee the site
- Trial code
- Registry title
- Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 27 May 2025
- Expected to end
- 30 Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo
- Lemborexant 10 MG
- Record updated
- 9 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with opioid use disorder who take prescribed buprenorphine and have long-term insomnia (trouble sleeping). It tests lemborexant against a placebo (dummy pill) for 8 weeks.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Opioid use disorder of at least moderate severity (DSM-5), with chronic insomnia. Insomnia Severity Index score of 13 or higher at screening and baseline.
- Earlier treatment
- Must be treated as an outpatient with sublingual buprenorphine film/tablets of 8mg to 24mg, or extended-release injectable buprenorphine. Must be on a stable dose for at least 4 weeks, with no planned change for 3 months. Cannot be receiving insomnia treatment now.
- Biomarker or test result
- Urine test positive for buprenorphine with a norbuprenorphine level the study clinician accepts. Urine test negative for non-prescribed drugs (except cannabinoids) and a negative alcohol test.
Main reasons for not taking part
- Sleep apnea or other sleep breathing problems, narcolepsy, sleepwalking or sleep paralysis
- Other alcohol or drug use disorder with non-prescribed use in the last 3 months, or cannabis use more than 3 days/week
- Taking benzodiazepines, other opioids, antipsychotics, sleep medicines, or drugs affecting CYP3A4
- Serious uncontrolled mental, heart, lung or nerve illness, or recent suicidal thoughts or attempt
- Pregnant or breastfeeding, or currently in prison or about to be
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Be 18 + years-of-age
- Meet current DSM-5 criteria for opioid use disorder (OUD) with at least moderate severity
- Receiving outpatient treatment for OUD with sublingual buprenorphine film/tablets ranging 8mg to 24mg or with extended-release injectable buprenorphine
- Stabilized on current buprenorphine dosage for at least 4 weeks without intention for dose change within next 3 months
- Screening urine toxicology positive for buprenorphine and an appropriate norbuprenorphine level as determined by a study clinician
- A screening urine toxicology negative for non-prescribed substances (except cannabinoids) with a negative breath (or oral fluid) alcohol screen
- Screen positive for chronic insomnia on the Insomnia Symptom Questionnaire (ISQ)
- Have an Insomnia Severity Index score at screening and baseline of 13 or higher
- Have no clinically significant medical or psychiatric disorder or condition, based on physical exam and medical history performed by study clinician, that in the judgement of the investigator would prevent participation or heighten safety risks
- Understand the study procedures and provide written informed consent in English language
- Access to necessary resources for completing virtual surveys and monitoring (i.e., computer or smartphone, internet or cell service)
Who cannot take part
- Currently receiving treatment for insomnia (behavioral or pharmacologic)
- Currently taking a medication to treat a sleep-related condition (e.g., zolpidem) or unable to discontinue over-the-counter drug or supplement used to treat sleep-related condition
- Currently taking benzodiazepines or other CNS active medications that may increase risk to the participant, per PI discretion (e.g., opioids other than buprenorphine, antipsychotics)
- Pregnant or breastfeeding; Females who are having sex that includes penile penetration must be non-pregnant, non-lactating, and either be of non-childbearing potential (e.g., sterilized via hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or at least 1 year post-menopausal) or of childbearing potential, and agree to use an acceptable form of contraception (e.g., IUD, hormonal implant, hormonal patch/ring/pill, condoms (male or female), etc.)
- Currently taking prescription or over-the counter drugs or dietary supplements known to significantly inhibit CYP3A4 (such as clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir); or CYP3A4 inducers (such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids)
- Currently taking lemborexant or any previous medically adverse reaction to lemborexant or other dual orexin receptor antagonists
- Current diagnosis of sleep-related breathing disorder, narcolepsy, somnambulism, or sleep paralysis
- A positive screen for sleep apnea by the following: Sleep Disorders Screening Battery (STOP-BAG >5) OR home sleep apnea test using WatchPAT with Apnea Hypopnea Index (AHI) with 3% drop in oxygen saturation > 10 OR >50% of respiratory events being central if AHI is between 5-10 OR Oxygen Desaturation < 88% for > 10 minutes, OR oxygen desaturation index (ODI) using 3% drop in oxygen saturation > 10
- Current DSM-5 diagnosis (any severity) of alcohol or drug use disorder (e.g., benzodiazepine, stimulant) with non-prescribed substance use within last 3 months; nicotine use disorder is not considered exclusionary
- Uncontrolled serious psychiatric disorder that would make study participation unsafe (such as Bipolar I Disorder, ADHD, Schizophrenia, schizoaffective disorders, major depressive disorder with psychotic features, or a neurological disorder)
- Uncontrolled neurological, cardiovascular, or pulmonary medical condition such as seizure disorder, recent myocardial infarction, stroke, hospitalization for chronic obstructive pulmonary disease
- Significant current suicidal or homicidal ideation (C-SSRS "yes" answers on questions 4 or 5) or a history of suicide attempt within the past 6 months
- Baseline ECG with clinically significant abnormal conduction or with QTc of greater than 450ms
- Any of the following lab abnormalities: ALT/AST 2 or more times the upper limit of normal, Total bilirubin 2 or more times the upper limit of normal, Creatinine 1.5 or more times the upper limit of normal
- Cannabis use > 3 days/week
- Currently incarcerated or pending incarceration
Where in United States
- VCU Institute for Drug and Alcohol StudiesRichmond, United StatesContact: Joyce Ruddley, RNTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn about how certain medications used to treat insomnia (e.g., Lemborexant) impact sleep, mood, and behavior in men and women with Opioid Use Disorder who are taking prescribed buprenorphine. The main questions it aims to answer are:
Read full original descriptionShow less
1. What is the effect of the study drug (lemborexant) on sleep outcomes? 2. What is the effect of the study drug (lemborexant) on impulsive behavior (as measured by computer test performance)? 3. What is the effect of the study drug (lemborexant) on mood and other behavior?
Researchers will compare lemborexant to placebo (e.g., sugar pill) to see if participants assigned to 8 weeks of treatment with lemborexant have greater improvements on the measures listed above.
Participants will take the study medication (or placebo) each night for 8 weeks and be asked to come for a total of 23 study visits. Most of these visits will be very short (15-30 minutes). The longer visits will include the screening visit (about 2-3 hrs), baseline visit (about 2.5 hrs), and the post-medication visit (about 2 hrs). Study visits will include things like taking surveys about sleep, drug use, and mood, completing urine drug testing, checking vital signs (e.g., blood pressure), and completing interviews with the study staff. Participants will also be asked to provide two blood samples (one during screening and one after taking the medication). For three two-week periods, participants will be asked to wear a watch to track sleep at home, and to keep a log of sleep and wake times.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Subjects who are randomized to placebo will receive identical capsules to the test product, administered orally.
- LemborexantTreatment being tested
Lemborexant (trade name Dayvigo), 10mg capsules, administered orally
Treatment: Lemborexant 10 MG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neurofunctional Phenotyping to Investigate the Role of the Orexin System at the Intersection of Opioid Use Disorder and Insomnia Among Women and Men Receiving Buprenorphine
- Plain-language title
- Lemborexant for insomnia in people with opioid use disorder taking buprenorphineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Record updated
- 9 July 2026